CT-guided microwave ablation of osteoid osteoma: Long-term outcome in 28 patients.


Journal

Diagnostic and interventional imaging
ISSN: 2211-5684
Titre abrégé: Diagn Interv Imaging
Pays: France
ID NLM: 101568499

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 19 03 2022
revised: 07 04 2022
accepted: 08 04 2022
pubmed: 7 5 2022
medline: 8 9 2022
entrez: 6 5 2022
Statut: ppublish

Résumé

The purpose of this study was to assess the long-term efficacy of CT-guided microwave ablation (MWA) in the treatment of osteoid osteoma. Secondary objectives were to assess early outcome and side-effects of MWA. Twenty-eight consecutive patients (18 men, 10 women) with a median age of 19.5 years (IQR: 16, 25.5) with a total of 28 non-spinal osteoid osteoma treated by CT-guided MWA were retrospectively included. The ablations were performed with a median power and duration of 60 Watt and 1 min 30 s, respectively. Pain referred to osteoid osteoma was assessed at predefined time points using a 0-10 numeric rating scale. At one month, contrast-enhanced follow-up MRI was performed to evaluate the nidus vascularization and the volume of necrosis induced by MWA. Clinical success was defined by the absence of osteoid osteoma-related pain, and technical success was defined by the presence of necrosis of the nidus on the one-month post-MWA MRI. Long term success rate was 93% (26/28) after a follow-up of 55.5 months (IQR: 25.75, 74.5) and technical success rate was 96 % (25/26). One late failure was observed after a patient had been declared cured at one month but the formal proof of a late recurrence of osteoid osteoma could not be brought. Three minor complications were reported including mild reversible superficial radial nerve injury with a skin burn (grade 2) in one patient and moderate skin burn only in two patients. Our results suggest that CT-guided MWA is an effective option for a minimally-invasive treatment of osteoid osteoma with a low rate of complication and no late recurrence.

Identifiants

pubmed: 35523700
pii: S2211-5684(22)00073-0
doi: 10.1016/j.diii.2022.04.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

427-432

Informations de copyright

Copyright © 2022 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflict of interests.

Auteurs

Lucie Parisot (L)

Department of Radiology, CHU de Besancon, 25030 Besancon, France.

Franck Grillet (F)

Department of Radiology, CHU de Besancon, 25030 Besancon, France; Department of Radiology, Centre Leon Bérard, 69008 Lyon, France.

Pierre Verdot (P)

Department of Radiology, CHU de Besancon, 25030 Besancon, France.

Alexis Danner (A)

Department of Radiology, CHU de Besancon, 25030 Besancon, France.

Eléonore Brumpt (E)

Department of Radiology, CHU de Besancon, 25030 Besancon, France; Nanomedicine laboratory EA4662. University of Franche-Comté, 25000 Besancon, France.

Sébastien Aubry (S)

Department of Radiology, CHU de Besancon, 25030 Besancon, France; Nanomedicine laboratory EA4662. University of Franche-Comté, 25000 Besancon, France. Electronic address: radio.aubry@free.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH